Skip to content

Author

L. Antilici

We have 2 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Clinical Profile of RSV Breakthrough Infections After Nirsevimab Introduction

The introduction of universal prophylaxis with nirsevimab for all children in their first epidemic season has substantially reduced the burden of respiratory syncytial virus (RSV). However, a small number of breakthrough infections continue to occur despite immunization, mostly in previously healthy infants, and these...

A. Vittucci, L. Antilici, Alessandra Salvatori et al. · 0 citations
Open access Aug 2026

Impact on Pediatric Respiratory Virus Epidemiology Following Nirsevimab Introduction.

Following nirsevimab introduction, pediatric ARI hospitalizations declined without evidence of viral replacement and the selective reduction in RSV coinfections suggests that RSV prevention may reduce infection complexity in addition to RSV-associated disease.

C. di Chiara, Vera Rigamonti, B. Campana et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.